Ortho Exhibits VITROS Range of Diagnostic Testing and Automation Solutions at MEDLAB Middle East 2021
|
By LabMedica International staff writers Posted on 24 Jun 2021 |

Image: VITROS® Automation Solutions (Photo courtesy of Ortho Clinical Diagnostics)
Ortho Clinical Diagnostics (Raritan, NJ, USA) exhibited its wide range of VITROS diagnostic testing and automation solutions at MEDLAB Middle East 2021.
Ortho’s VITROS Automation Solutions presented at the event are open, flexible and scalable solutions. Versatile, effective, and reliable, VITROS Automation Solutions combined with VITROS Chemistry and Immunodiagnostic Systems delivers high-quality results, faster than VITROS Systems alone. Ortho VITROS Systems makes labs powerfully efficient with minimal training time, six-month calibration, and a 96.5% first pass yield that erases the need for repeat testing. While non-VITROS systems use large, costly amounts of purified water, one VITROS System saves 160,000 liters of water per year. Ortho showcased the VITROS XT Systems that embrace DIGITAL CHEMISTRY™ and are powered by a new digital reflectometer, connecting lab ecosystems better than ever before, driving efficiency, productivity and improving the quality of care provided to patients.
Ortho also highlighted its COVID-19 testing solutions at the event, including the VITROS antibody assays for COVID-19. This included VITROS Anti-SARS-COV-2 Total test which qualitatively measures total (ALL) antibodies to the SARS-CoV-2 virus (IgG, IgM, IgA and other isotypes) and therefore has the widest clinical utility to measure immune response. This antibody test can be used to aid in the diagnosis of acute or past infection in conjunction with other laboratory tests and or clinical information. In addition, this test may be used in population surveillance for viral exposure. Similarly, the VITROS Anti-SARS-COV-2 IgG test qualitatively measures IgG Antibodies to the SARS-CoV-2 virus. This antibody test has long-term applicability in identifying patients with an adaptive immune response, indicating recent or prior infection. In addition, this test may be used in population surveillance for viral exposure. In addition Ortho showcased the VITROS SARS-CoV-2 Antigen Test that produces accurate, clinically reliable results on its high-volume VITROS Systems. These analyzers normally run a broad menu of over 150 different tests from blood and body fluid samples, but now are also able to run samples derived from swabs.
Related Links:
Ortho Clinical Diagnostics
Ortho’s VITROS Automation Solutions presented at the event are open, flexible and scalable solutions. Versatile, effective, and reliable, VITROS Automation Solutions combined with VITROS Chemistry and Immunodiagnostic Systems delivers high-quality results, faster than VITROS Systems alone. Ortho VITROS Systems makes labs powerfully efficient with minimal training time, six-month calibration, and a 96.5% first pass yield that erases the need for repeat testing. While non-VITROS systems use large, costly amounts of purified water, one VITROS System saves 160,000 liters of water per year. Ortho showcased the VITROS XT Systems that embrace DIGITAL CHEMISTRY™ and are powered by a new digital reflectometer, connecting lab ecosystems better than ever before, driving efficiency, productivity and improving the quality of care provided to patients.
Ortho also highlighted its COVID-19 testing solutions at the event, including the VITROS antibody assays for COVID-19. This included VITROS Anti-SARS-COV-2 Total test which qualitatively measures total (ALL) antibodies to the SARS-CoV-2 virus (IgG, IgM, IgA and other isotypes) and therefore has the widest clinical utility to measure immune response. This antibody test can be used to aid in the diagnosis of acute or past infection in conjunction with other laboratory tests and or clinical information. In addition, this test may be used in population surveillance for viral exposure. Similarly, the VITROS Anti-SARS-COV-2 IgG test qualitatively measures IgG Antibodies to the SARS-CoV-2 virus. This antibody test has long-term applicability in identifying patients with an adaptive immune response, indicating recent or prior infection. In addition, this test may be used in population surveillance for viral exposure. In addition Ortho showcased the VITROS SARS-CoV-2 Antigen Test that produces accurate, clinically reliable results on its high-volume VITROS Systems. These analyzers normally run a broad menu of over 150 different tests from blood and body fluid samples, but now are also able to run samples derived from swabs.
Related Links:
Ortho Clinical Diagnostics
Latest MEDLAB 2021 News
- MP Biomedicals Exhibits Diagnostics Kits and Sample Prep Solutions at MEDLAB Middle East 2021
- BD Demonstrates Latest Medtech Innovations at MEDLAB Middle East 2021
- Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021
- Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021
- Horiba Medical Exhibits New Generation of Automated Hematology Analyzers at MEDLAB Middle East 2021
- Rad Source Technologies Introduces Premier X-Ray Blood Irradiator RS 3400 at MEDLAB Middle East 2021
- Nova Biomedical Showcases Advanced Point-of-Care Capillary Blood Analyzers at MEDLAB Middle East 2021
- Erba Mannheim Showcases Exciting New Introductions at MEDLAB Middle East 2021
- Bioperfectus Presents Advanced Infectious Disease Diagnostic Solutions at MEDLAB Middle East 2021
- PerkinElmer Demonstrates High-Throughput MSMS Dried Blood Spot Screening Solutions at Medlab Middle East 2021
- PerkinElmer’s EUROIMMUN Presents Novel Ultrafast Automated Microscope and Intelligent Software for State-of-the-Art Diagnostics
- LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event
- Quidel Showcases Comprehensive Suite of COVID-19 Testing Solutions at MEDLAB Middle East 2021
- MEDLAB Middle East 2021 Brings World of Laboratory Medicine Together Under ‘United by Business’ Show Theme
Channels
Clinical Chemistry
view channel
Study Evaluates Alzheimer’s Blood Biomarker Across Racial and Ethnic Groups
Alzheimer’s disease trials increasingly depend on identifying cognitively unimpaired people who already have elevated brain amyloid. Blood biomarkers may help reduce reliance on positron emission tomography... Read more
Blood Protein May Help Identify Treatment-Resistant Psychosis
Psychotic disorders, including schizophrenia, are diagnosed primarily through assessment of symptoms and behaviors such as hallucinations, delusions, and disordered thinking. Treatment-resistant psychosis... Read moreMolecular Diagnostics
view channel
Blood-Based Metagenomic Test Detects Wide Range of Pathogens from Single Sample
Infectious disease diagnosis can be challenging when the causative pathogen is unknown at the start of evaluation. Conventional testing may require multiple targeted assays, delaying answers for patients... Read more
New RNA Detection Tool Shows Promise for HIV and Other Viral Testing
RNA viruses such as human immunodeficiency virus (HIV) require assays that can detect very low levels of viral genetic material. Clinical and environmental testing can also expose enzymes to harsh assay... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
FDA Approval Adds Automated Testing Option for Parvovirus B19 Serology
Human Parvovirus B19 is a highly contagious erythrovirus transmitted mainly through respiratory droplets and close contact. Diagnosis relies on IgM antibodies to detect active infection and IgG antibodies... Read more
Blood-Based Immune Aging Map Could Help Spot Disease Risk Earlier
Chronological age does not always reflect immune health or future disease risk. Two adults of the same age can have immune systems that age very differently, with some remaining resilient while others... Read moreMicrobiology
view channel
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read more
Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms
Long Covid can involve persistent respiratory, cognitive, and gastrointestinal symptoms after acute infection, creating a difficult diagnostic and management challenge. Because COVID-19 initially affects... Read morePathology
view channel
Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
Barrett’s esophagus is a precancerous condition associated with increased risk of esophageal adenocarcinoma. Routine endoscopic biopsy findings guide surveillance and therapy, but histopathology may not... Read more
Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
Digital pathology is reshaping how laboratories manage case review, image analysis, and collaboration. As diagnostic workflows become more complex, pathology teams need platforms that can support digital... Read moreTechnology
view channelLaser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read moreIndustry
view channel
Global TB Summit Connects Diagnostic Testing With Prevention and Clinical Care
Tuberculosis remains a major global infectious disease challenge despite declining deaths. In 2024, an estimated 10.7 million people worldwide developed the disease and nearly 1.2 million died from it.... Read more








